Drug intelligence / Profile preview

autologous platelet-rich fibrin glue

Development stage: Phase 1
Lead developer: Jinling Hospital
Modality: Cell Therapies
Administration: Topical

Overview

Autologous platelet-rich fibrin glue (PRFG) is a biologic therapy prepared from a patient's own blood, containing concentrated fibrinogen, factor XIII, thrombin, calcium, platelets, and leukocytes. It is used as a surgical sealant to treat low-output enterocutaneous fistulas (ECFs). When applied to the fistula tract, it forms a coagulum that mechanically seals the tract and releases growth factors from platelets to promote tissue healing and fistula closure. Jinling Hospital in China has led multi-center clinical trials evaluating its efficacy compared to commercial porcine-derived fibrin glue and standard drainage cessation.

Other names: autologous fibrin glueplatelet-rich fibrin glueautologous PRFG

Beyond the preview

Go deeper on autologous platelet-rich fibrin glue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous platelet-rich fibrin glue.

Explore the full profile